Levoxa (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. Inhibiting these targets prevents bacterial cells from multiplying, leading to rapid bactericidal activity against a broad range of Gram‑negative and Gram‑positive organisms.

The specific dosage of Levoxa is determined by the prescribing clinician based on the infection type, severity, patient age, renal function, and other clinical factors. Healthcare professionals set the appropriate dose and treatment duration for each individual case.

Levoxa is classified as a pregnancy‑category drug with limited data. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus. Likewise, breastfeeding mothers should consult their physician, as levofloxacin can be excreted in breast milk.

To request Levoxa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levoxa (levofloxacin) is the L‑isomer of ofloxacin, offering higher potency and better tissue penetration than many older fluoroquinolones. It provides a broader spectrum against Gram‑negative pathogens and requires once‑daily dosing for many infections, which can improve patient adherence compared with agents that need multiple daily doses.

Levoxa should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Levoxa is taken orally, usually as a tablet or oral suspension, with or without food. The exact form and dosing schedule are prescribed by the treating physician, who will also advise on any necessary timing adjustments with other medications.

Serious risks include tendon rupture or tendinitis, especially in older adults or those on corticosteroids; QT interval prolongation that can lead to cardiac arrhythmias; and severe allergic reactions such as anaphylaxis. Patients should be monitored for these events and advised to seek immediate medical attention if they occur.

Levoxa is contraindicated in patients with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any of the product’s excipients. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, and in patients with significant QT prolongation unless benefits clearly outweigh risks.